The PMDA is Japan's national regulator for pharmaceuticals and medical devices. Its full name is the Pharmaceuticals and Medical Devices Agency (独立行政法人医薬品医療機器総合機構), and it was established on 1 April 2004 as an incorporated administrative agency under the oversight of the Ministry of Health, Labour and Welfare. It reviews drugs, medical devices, in-vitro diagnostics and regenerative medicine products before they reach the Japanese market, and monitors their safety afterwards.

What does PMDA stand for?

PMDA stands for the Pharmaceuticals and Medical Devices Agency. In Japanese it is the 医薬品医療機器総合機構, usually shortened to PMDA in both languages.

PMDA describes its mandate as three pillars: review, safety, and relief. It conducts the scientific review of applications to market drugs and devices in Japan; it runs post-market pharmacovigilance, adverse-event reporting and GMP and GCP inspections; and it administers a relief system that compensates patients harmed by properly used pharmaceuticals. The third function has no direct equivalent at the FDA or EMA.

Is the PMDA Japan's version of the FDA?

It is the closest counterpart, but the mandates differ in three important ways. PMDA does not regulate food, which in Japan sits with the Consumer Affairs Agency and MHLW. PMDA does not issue the final marketing approval; it reviews and recommends, and MHLW grants the authorisation. And PMDA does not set prices, which are determined separately through MHLW's Chuikyo council under national health insurance.

Does the PMDA approve drugs in Japan?

Not formally. PMDA carries out the scientific review and makes a recommendation, but the Ministry of Health, Labour and Welfare issues the marketing authorisation itself. In practice this means a Japan strategy has to engage both bodies: PMDA on the science, and MHLW on the policy and reimbursement decisions that determine whether an approved product is commercially viable.

How long does PMDA review take?

It depends on the pathway. Standard new-drug review runs to a target of roughly twelve months, while priority review targets around nine. Products with Sakigake designation, orphan designation or conditional early approval can move faster still. Timelines assume the sponsor has used PMDA's pre-submission consultations; skipping them is one of the most common causes of delay for foreign sponsors.

How long is the clinical trial notification waiting period in Japan?

Thirty days. Under Article 80-2(2) of the PMD Act, a clinical trial notification for a drug carries a published standard processing period of 30 days and no fee, and roughly 558 are filed a year. Subsequent changes to an already-notified trial plan are processed in one day, with about 5,660 filed annually. The initial notification is the gate; amendments are routine.

How long does PMDA approval take?

It depends on the product class, and the published standard processing periods are long. Medical device marketing approval runs to 10 months, in-vitro diagnostic approval to 12 months, and a partial change to an already-approved drug also 12 months, each with a fee. Against that, a minor change notification is processed in one week with no fee. Whether a change is minor or partial is therefore a scheduling decision worth roughly fifty times its administrative weight.

PMDA Japan: What the Pharmaceuticals and Medical Devices Agency Does

The PMDA is Japan’s regulator for pharmaceuticals and medical devices. Formally the Pharmaceuticals and Medical Devices Agency (独立行政法人医薬品医療機器総合機構), it was established on 1 April 2004 and operates under the oversight of the Ministry of Health, Labour and Welfare (MHLW). It reviews drugs, devices, diagnostics and regenerative medicine products before they reach the Japanese market, monitors their safety once they are on it, and compensates patients harmed by side effects.

PMDA describes that mandate as three pillars: review, safety, and relief. The third is unusual: no equivalent sits inside the FDA or EMA, and it is funded by levies on manufacturers rather than through the courts.

One point causes more confusion than any other, and it matters commercially. PMDA does not itself approve products. It conducts the scientific review and makes a recommendation; MHLW issues the marketing authorisation. Pricing is decided separately again, by MHLW’s Chuikyo council. Approval, authorisation and reimbursement are three different decisions taken by two different bodies.

For pharmaceutical and medical-device companies entering or operating in Japan, PMDA is nonetheless the single most consequential regulatory counterpart. It shapes global regulatory science through its harmonisation work with the FDA and EMA, and understanding how it interacts with MHLW above it is foundational for any credible Japan market-access strategy.

The PMDA is also central to public policy in Japan on healthcare innovation. Its review timelines, expedited pathways, and regulatory science initiatives directly shape whether Japan receives new therapies and devices years ahead of, or behind, other major markets.

Mandate and legal basis

PMDA was created under the Act on the Pharmaceuticals and Medical Devices Agency, consolidating review functions previously distributed across MHLW and its affiliated bodies. Its legal form is an incorporated administrative agency (独立行政法人, dokuritsu gyosei hojin), which gives it operational independence in how it conducts reviews while leaving policy and approval authority with the ministry.

Its regulatory authority derives from the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, commonly the PMD Act (薬機法, previously the Pharmaceutical Affairs Law). The PMD Act defines product categories, approval standards, post-market obligations, and enforcement powers.

This split is more than procedural. It means that for high-stakes products, engagement must be coordinated across both PMDA’s scientific review teams and MHLW’s policy divisions, including the Pharmaceutical Safety and Environmental Health Bureau and the Health Insurance Bureau, the latter of which governs reimbursement pricing.

Organisational structure

The PMDA is organised into specialised offices covering:

New drug review (divided by therapeutic area: oncology, cardiovascular, CNS, infectious disease, vaccines, and others).
Generic drug review.
Medical device review (divided by device category).
Regenerative medicine and cell and gene therapy review, a specialised function reflecting Japan’s early and distinctive regulatory framework for these products.
Quality, non-clinical, and clinical safety assessment teams.
Safety management and post-market surveillance.
Relief services for health damage caused by pharmaceutical side effects or device malfunctions.
International cooperation with counterpart regulators.

Review teams are typically organised around senior reviewers with deep therapeutic-area expertise, supported by clinical, statistical, pharmacology, and quality specialists. The agency has expanded its workforce substantially since 2004 and has made continued investment in reviewer capacity a strategic priority.

Core functions

Pre-market evaluation and approval

PMDA reviews applications for new drugs, generics, medical devices, in-vitro diagnostics, regenerative medicine products, and combination products. Review standards follow ICH guidelines for pharmaceuticals and IMDRF principles for devices, adapted to Japanese statutory requirements.

The agency offers several consultation pathways (pre-IND, end-of-Phase II, pre-NDA, and similar) that are strongly recommended, and for many product types effectively expected, before submission. These consultations shape the review trajectory and resolve points that would otherwise delay approval.

Expedited review pathways

Japan has one of the most developed sets of expedited regulatory pathways in the world.

Priority Review for products addressing serious conditions with significant clinical benefit.
Orphan Drug and Orphan Medical Device Designation with associated review support.
Sakigake Designation (Pioneer/Leading Designation) for innovative products first developed in Japan or first submitted to Japan, offering prioritised consultation and review.
Conditional Early Approval for products where conventional confirmatory trials are difficult to complete but adequate evidence supports early access.
The Act on the Safety of Regenerative Medicine and PMD Act pathways for regenerative medical products, under which certain cell and gene therapies can reach the market with conditional time-limited approvals pending confirmatory post-marketing evidence.

For companies developing innovative therapies, these pathways can materially accelerate Japanese market entry, but only when the commercial and regulatory strategy is designed from the start to use them.

Post-market safety and quality

PMDA administers pharmacovigilance, adverse-event reporting, Good Manufacturing Practice (GMP) inspections, Good Clinical Practice (GCP) inspections, and quality assurance throughout the product lifecycle. Post-market obligations in Japan are substantial and differ in several respects from FDA and EMA frameworks: risk management plans, re-examination periods, and periodic safety updates all follow Japan-specific rules.

Relief services

A distinctive feature of PMDA’s mandate is the Adverse Drug Reaction Relief System, which provides compensation to patients who suffer health damage from appropriately used pharmaceuticals or device malfunctions. The system is funded by levies on pharmaceutical and device manufacturers and operates outside the civil liability system.

International harmonisation

PMDA is a leading contributor to international regulatory harmonisation. It participates actively in:

ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use).
IMDRF (International Medical Device Regulators Forum).
Bilateral cooperation agreements with the FDA, EMA, Health Canada, TGA, and Asian counterparts.
Joint-review and work-sharing pilots with counterpart regulators for select products.

For sponsors, the practical implication is that clinical data generated under ICH guidance is generally acceptable in Japan, subject to PMDA’s assessment of whether it adequately represents the Japanese population. Ethnic-sensitivity considerations and, in some cases, requirements for Japanese bridging or confirmatory data remain distinctive features of Japanese review.

How the PMDA interacts with MHLW and reimbursement

Market authorisation is only one part of Japan market access. The MHLW’s Central Social Insurance Medical Council (Chuikyo) determines reimbursement pricing under the National Health Insurance system, which is what ultimately determines the commercial viability of a product. Pricing rules (including foreign-price adjustment, market-expansion repricing, and the cost-effectiveness assessment framework) have undergone multiple revisions through the mid-2020s and continue to evolve.

A credible Japan strategy therefore runs two parallel tracks: scientific engagement with PMDA on approval, and health-economic and policy engagement with MHLW and Chuikyo on reimbursement.

Evolving priorities

Several themes shape the PMDA’s current agenda as of 2026.

Advanced therapies. Regenerative medicine, cell and gene therapy, RNA therapeutics, and combination products continue to stretch conventional frameworks.
AI and software as a medical device (SaMD). Review frameworks for AI-enabled medical software are being developed in parallel with METI and MHLW work, and align with the AI Guidelines for Business and AISI initiatives.
Real-world data and real-world evidence. PMDA has invested in MID-NET and similar platforms to support RWE-based regulatory decisions.
Review capacity. Matching reviewer resources to growing application volumes remains a strategic priority.
Asia-Pacific leadership. PMDA is positioning itself as an anchor regulator for ASEAN and other Asian authorities, including through training and regulatory-science cooperation.

What this means for pharma and medtech companies operating in Japan

For sponsors, the practical implications are consistent.

Engage PMDA early. Pre-consultation pathways are not optional in a serious Japan strategy. They shape study design, pivotal trial strategy, and submission content.
Plan for Japan-specific data requirements. Bridging strategies, Japanese Phase I pharmacokinetic studies where appropriate, and inclusion of Japanese subjects in global pivotal trials all need to be considered at the protocol-design stage.
Integrate reimbursement strategy from the start. Approval without an economically viable price achieves little. MHLW and Chuikyo engagement, health-economic modelling, and policy advocacy belong on the critical path.
Use expedited pathways where warranted. Orphan, Sakigake, and Priority Review designations can materially shift timelines, but require strategic positioning during development.
Build capacity for post-market obligations. Japan’s post-market regime is substantial and Japan-specific; compliance infrastructure cannot be copy-pasted from FDA or EMA frameworks.

What the published timelines actually are

Japan publishes a standard processing period for each administrative procedure, with its legal basis, fee status and annual filing volume. For the procedures a sponsor deals with:

Procedure	Legal basis	Standard period	Fee	Filings/year
Clinical trial notification, drug	PMD Act Art. 80-2(2)	30 days	none	~558
Change to a notified trial plan	Enforcement Reg. Art. 270	1 day	none	~5,660
Medical device marketing approval	PMD Act Art. 23-2-5(1)	10 months	yes	~351
In-vitro diagnostic approval	PMD Act Art. 23-2-5(1)	12 months	yes	~63
Partial change to an approved item	PMD Act Art. 14(15)	12 months	yes	~3,083
Minor change notification	PMD Act Art. 14(16)	1 week	none	~21,232

Two things stand out. The 30-day clinical trial notification is the entry gate, and it is the point at which a Japanese development plan becomes visible to the regulator. And the one week versus twelve months split between a minor change and a partial change is the largest single scheduling variable in the post-approval life of a product, which is why the classification of a proposed change is worth arguing carefully rather than conceding.

The safety side runs at a different scale entirely: adverse reaction and infection reporting for investigational drugs alone accounts for roughly 165,782 filings a year, with a further 1,935 for devices and 1,202 for processed cell products.

A caution on reading these: a standard processing period is the reviewing body’s own target and generally excludes time while an application sits with the applicant for correction. Treat them as a floor.

Why this matters for public affairs in Japan

The PMDA is scientifically rigorous, increasingly internationally connected, and institutionally embedded within a broader MHLW and Diet policy environment that shapes healthcare reimbursement, data rules, and innovation priorities. Effective engagement with PMDA alone is not sufficient. It needs to be combined with public affairs and government relations engagement across MHLW, the LDP’s healthcare policy structures, Chuikyo, and the relevant Diet committees.

Gemini Group supports pharmaceutical, medical device, diagnostics, and digital health companies in navigating Japan’s regulatory and reimbursement environment: mapping PMDA and MHLW stakeholders, aligning regulatory strategy with policy advocacy, and building engagement plans that accelerate market access. Contact us to discuss how your organisation can work effectively with PMDA and the broader Japanese healthcare policy landscape.

For the wider policy environment this agency sits in, see our sector page on healthcare and life sciences policy in Japan.